Capitalized Expenditures. Make Capitalized Expenditures in excess of $500,000 in the aggregate in any fiscal year of Borrower.
Appears in 4 contracts
Samples: Loan and Security Agreement (Cirius Therapeutics, Inc.), Loan and Security Agreement (Cirius Therapeutics, Inc.), Loan and Security Agreement (Liquidia Technologies Inc)
Capitalized Expenditures. Make Capitalized Expenditures in excess of Forty Million Dollars ($500,000 40,000,000) in the aggregate in any during each fiscal year of Borrower.
Appears in 4 contracts
Samples: Loan and Security Agreement (Precision Biosciences Inc), Loan and Security Agreement (Precision Biosciences Inc), Loan and Security Agreement (Precision Biosciences Inc)
Capitalized Expenditures. Make Capitalized Expenditures in excess of $500,000 150,000 in the aggregate in any fiscal year of Borrower.
Appears in 3 contracts
Samples: Loan and Security Agreement, Loan and Security Agreement (Rubius Therapeutics, Inc.), Loan and Security Agreement (Rubius Therapeutics, Inc.)
Capitalized Expenditures. Make Capitalized Expenditures in excess of Twenty Five Million Dollars ($500,000 25,000,000) in the aggregate for fiscal years 2020 and 2021, or in excess of One Million Five Hundred Thousand Dollars ($1,500,000) in the aggregate in any fiscal year of Borrowerthereafter.
Appears in 2 contracts
Samples: Loan and Security Agreement (Adicet Bio, Inc.), Loan and Security Agreement (resTORbio, Inc.)
Capitalized Expenditures. Make Capitalized Expenditures in excess of $500,000 350,000 in the aggregate in any fiscal year of Borrower.
Appears in 1 contract
Samples: Loan and Security Agreement (Werewolf Therapeutics, Inc.)
Capitalized Expenditures. Make Capitalized Expenditures in excess of $500,000 250,000 in the aggregate in any fiscal year of Borrower.
Appears in 1 contract
Samples: Loan and Security Agreement (Kaleido Biosciences, Inc.)
